Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2366 - Immune Checkpoints and T-Lymphocytes as Immunotherapeutic Target in the Treatment of Sebaceous Gland Carcinoma

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Tumour Immunology

Tumour Site

Presenters

Lata Singh

Citation

Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

Authors

L. Singh1, M.K. Singh2, N. Pushker3, S. Bakhshi4, M.A. Rizvi1, S. Sen2, S. Kashyap2

Author affiliations

  • 1 Biosciences, Jamia Millia Islamia, 110025 - New Delhi/IN
  • 2 Ocular Pathology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 3 Ophthalmology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 4 Medical Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2366

Background

Immune checkpoint blockade strategies have gained attention in the treatment/prognosis of cancers via targeting the PD-1/PD-L1 pathway or in combination with the CTLA-4 blockade and are currently in clinical trials. The present study investigated the expression of PD-1, PD-L1, CTLA-4, CD4 and CD8 proteins and their prognostic value in the tumor microenvironment of sebaceous gland carcinoma patients (SGC).

Methods

Stromal and tumor cells expressing PD-1, PD-L1, CTLA-4, CD4 and CD8 protein were assessed in 52 cases of sebaceous gland carcinoma by Immunohistochemistry and their mRNA expression was measured by quantitative Reverse-Transcriptase PCR (qRT-PCR). Kaplan–Meier curves and Cox proportional hazard models, analyzed the correlation of proteins with clinicopathological parameters and disease-free survival.

Results

Pagetoid spread was the frequent histopathological high-risk factor in our study. Expression of PD-L1 was found to be more common in tumor cells than stromal cells. In univariate analysis, patients expressing PD-1 and PD-L1 in tumor cells were associated with reduced disease-free survival, whereas stromal-PD-L1 showed an increased survival of the patients (p < 0.05). However, in multivariate analysis, expression of PD-1 in tumor cells was found to be an independent prognostic factor for poor survival.

Conclusions

This is the first report describing the association of clinicopathological features and outcomes of immune checkpoint expression along with T-Lymphocytes in sebaceous gland carcinoma. These results support the consideration that PD-1/PD-L1 pathway might play an important role in tumor microenvironment for mediating immune response in the pathogenesis of sebaceous gland carcinoma patients.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.